Key result
A 68-year-old woman with hepatic angiosarcoma complicated by disseminated intravascular coagulopathy died 2 months after diagnosis despite treatment with doxorubicin.
Why the study?
Hepatic angiosarcoma is a rare, aggressive tumor without established, effective treatment guidelines, and knowledge about its manifestations such as paraneoplastic disseminated intravascular coagulopathy is limited.
Case Report (n=1)
Hepatic angiosarcoma is a rare, aggressive tumor that can be complicated by paraneoplastic disseminated intravascular coagulopathy, leading to a rapid and fatal course despite chemotherapy.
Signals rapid mortality in hepatic angiosarcoma with DIC despite doxorubicin; leaves open need for novel therapies.
Background: Hepatic angiosarcoma is an uncommon, malignant, primary liver tumor, comprising 2% of liver cancers and accounting for < 1% of all sarcomas. Patients usually present with nonspecific symptoms, such as fatigue, weight loss, right upper quadrant pain, anemia, which leads to late diagnosis of an advanced stage tumor. The median life expectancy after the diagnosis of hepatic angiosarcoma is about 6 months, with only 3% of patients surviving more than 2 years. Liver failure and hemoperitoneum are the leading causes of death in patients with liver angiosarcoma. In rarer cases, it might cause paraneoplastic syndromes such as disseminated intravascular coagulopathy. The treatment of angiosarcomas is complicated as there are no established and effective treatment guidelines due to the tumor's low frequency and aggressive nature. Case summary: /l). The abdominal ultrasound and computed tomography scan showed multiple lesions throughout the liver, spleen and kidneys. After the histological examination of the liver biopsy, the patient was diagnosed with hepatic angiosarcoma. The treatment with first-line chemotherapy (doxorubicin) was initiated despite ongoing paraneoplastic syndrome - disseminative intravascular coagulopathy. However, the disease was terminal, and the patient died 2 months since diagnosed. Conclusions: Hepatic angiosarcoma is a rare and terminal tumor. Therefore, knowledge about its manifestations and effective treatment methods is lacking. Disseminative intravascular coagulopathy is a unique clinical characteristic of angiosarcoma seen in a subset of patients.
No takes yet. Share an insight, caveat, or question.
Strainienė et al. (2021) conducted a case report in Hepatic angiosarcoma with disseminated intravascular coagulopathy (n=1). Doxorubicin was evaluated on Survival. A 68-year-old woman with hepatic angiosarcoma complicated by disseminated intravascular coagulopathy died 2 months after diagnosis despite treatment with doxorubicin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: